Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US8075900: Melanoma associated peptide analogues and vaccines against melanoma


Filing Information

Inventor(s) Carl Gustav Figdor · Gosse Jan Adema ·
Assignee(s) The United States of America, as represented by the Secretary, Department of Health and Human Services ·
Attorney/Agent(s) Leydig, Voit & Mayer ·
Primary Examiner Stephen Rawlings ·
Application Number US12961217
Filing date 12/06/2010
Issue date 12/13/2011
Prior Publication Data
Predicted expiration date 07/08/2017
U.S. Classifications 424/185.1  · 514/15  · 530/328  ·
International Classifications A61K3900  ·
Kind CodeB2
This application is a divisional of U.S. patent application Ser. No. 12/337,834, filed Dec. 18, 2008, now U.S. Pat. No. 7,846,450, which is a divisional of U.S. patent application Ser. No. 10/808,681, filed Mar. 25, 2004 (now abandoned), which is a continuation of application Ser. No. 09/214,836 filed Oct. 4, 1999 (now abandoned), which was the National Stage of International Application No. PCT/EP97/03712 filed Jul. 8, 1997 and having a priority date of Jul. 11, 1996. The disclosure of each of these related applications is incorporated herein their entireties.
Foreign Priority EP96201945 - 07/11/1996 ·
3 Claims, 5 Drawings


The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof; vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer.

Independent Claims | See all claims (3)

  1. 1. A gp100 peptide consisting of SEQ ID NO: 17.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US4405712 The United States of America as represented by the Department of Health and Human Services Vande Woude et al. Sep 1983
US4485086 WONG DENNIS W Wong Nov 1984
US4497796 The Regents of the University of California Salser et al. Feb 1985
US4727028 Eli Lilly and Company Santerre et al. Feb 1988
US4740463 Massachusetts Institute of Technology Weinberg et al. Apr 1988
US5190931 The Research Foundation of State University of New York Inouye Mar 1993
US5208149 The Research Foundation of State University of New York Inouye May 1993
US5262177 Oncogen Brown et al. Nov 1993
US5342774 Ludwig Institute for Cancer Research Boon et al. Aug 1994
US5376531 Northwestern University Anderson et al. Dec 1994
US5518913 National Research Council of Canada Massie et al. May 1996
US5639860 Kyowa Hakko Kogyo Co., Ltd. Tanaka et al. Jun 1997
US5643873 Affymax Technologies N.V. Barrett et al. Jul 1997
US5648458 Affymax Technologies N.V. Cwirla et al. Jul 1997
US5728802 Affymax Technologies N.V. Barrett et al. Mar 1998
US5731172 Sumitomo Pharmaceuticals Company, Ltd. Saito et al. Mar 1998
US5783567 Pangaea Pharmaceuticals, Inc. Hedley et al. Jul 1998
US5837511 Cornell Research Foundation, Inc. Falck-Pedersen et al. Nov 1998
US5844075 The United States of America as represented by the Department of Health and Human Services Kawakami et al. Dec 1998
US5874560 The United States of America as represented by the Department of Health and Human Services Kawakami et al. Feb 1999
US5891432 The Immune Response Corporation Hoo Apr 1999
US5965381 Ludwig Institute for Cancer Research van der Bruggen et al. Oct 1999
US5965535 Ludwig Institute for Cancer Research Chaux et al. Oct 1999
US5994106 GenVec, Inc. Kovesdi et al. Nov 1999
US5994128 IntroGene B.V. Fallaux et al. Nov 1999
US5994523 The United States of America as represented by the Department of Health and Human Services Kawakami et al. Nov 1999
US6033908 b.v. IntroGene Bout et al. Mar 2000
US6040174 Transgene S.A. Imler et al. Mar 2000
US6194195 Kyowa Hakko Kogyo Co., Ltd. Tanaka et al. Feb 2001
US6204052 Introgene B.V. Bout et al. Mar 2001
US6245525 Ludwig Institute for Cancer Research Martelange et al. Jun 2001
US6270778 The United States of America as represented by the Department of Health and Human Services Kawakami et al. Aug 2001
US6291430 Ludwig Institute for Cancer Research Chaux et al. Sep 2001
US6303756 Ludwig Institute for Cancer Research Martelange et al. Oct 2001
US6369211 Ludwig Institute for Cancer Research Chaux et al. Apr 2002
US6407063 Ludwig Institute for Cancer Research Luiten et al. Jun 2002
US6426217 Ludwig Institute for Cancer Research Chaux et al. Jul 2002
US6500919 IntroGene B.V. Adema et al. Dec 2002
US6537560 The United States of America as represented by the Department of Health and Human Services Kawakami et al. Mar 2003
US7846450 United States of America, as represented by the Secretary, Department of Health and Human Services Figdor et al. Dec 2010
US20020076392 Hoo Jun 2002
US20030096787 Perricaudet et al. May 2003
US20030144482 KAWAKAMI YUTAKA Kawakami et al. Jul 2003
US20040156861 Figdor et al. Aug 2004

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
EP0668350Crucell Holland B.V.Aug 1995
JP927482Jan 1997
WO199221767Dec 1992
WO199314189Apr 1993
WO199423067Oct 1994
WO199428152Dec 1994
WO199502697Jan 1995
WO199522561Aug 1995
WO199529193Nov 1995
WO199802538Jan 1998
WO199831398Jul 1998
WO199914326Mar 1999
WO199945098Sep 1999
WO200020445Pascal CHAUXApr 2000

Other Publications

Arceci, RJ., The potential for antitumor vaccination in acute myelogenous leukemia, Journal of Molecular Medicine, 1998, pp. 80-93, vol. 76.
Bakker et al., Int. J. Cancer, Jan. 27, 1997, pp. 302-309, vol. 70 (3).
Bodey et al., Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Research, 2000, pp. 2665-2676, vol. 20.
Boon, T., Toward a genetic analysis of tumor rejection antigens, Advances in Cancer Research, 1992, pp. 177-210, vol. 58.
Burgess et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic: Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, J. Cell Bio1,1990, 11:2129-2138.
Cox et al., Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines, Science, 1994, pp. 716-719, vol. 264.
Curti, Crit. Rev. Oncol/Hematol. 14:29-39, 1993.
De Vries et al., Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions, Cancer Research, 1997, pp. 3223-3229, vol. 57, No. 15.
Ezzell, C., Cancer “vaccines”: an idea whose time has come?, Journal of NIH Research, pp. 46-49, vol. 7, 1995.
Gao et al., Tumor vaccination that enhances antitumor T-cell responses does not inhibit the growth of established tumor, Journal of Immunotherapy, 2000, pp. 643-653, vol. 23, No. 6.
Gura, T., Systems for identifying drugs are often faulty, Science, 1997, pp. 1041-1042, vol. 278.
Hu et al., Enhancement of cytolytic T lymphocyte precursor frequence in melanoma patients following immunization with MAGE-1 peptide, Cancer Research, 1996, pp. 2479-2483, vol. 56.
Jaeger et al, Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo, International Journal of Cancer, 1996, pp. 162-169, vol. 66, No. 2.
Kristensen et al., Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor, Febs Letters, Dec. 1990, pp. 151-155, vol. 256, No. 1,2.
Lee et al., Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, Journal of Immunology, 1999, pp. 6292-6300, vol. 163.
Mukherji et al., Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization, proceedings of the National Academy of Science, 1995, pp. 8078-8082, vol. 92.
Gillies et al., Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities, Human Antibody. Hybridomas, 1990, vol. 1, No. 1, pp. 47-54.
Jain, Sci. Am. 271:58-65, 1994.
Kwon et al., A melanocyte-specific gene. Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12, Proceedings of the National Academy of Sciences of USA, 88(20)9228-9232, Oct. 15, 1991, Washington D.C., USA.
Lazar et al., Transforming Growth Factor a: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell Biol., 1988, vol. 8, pp. 1247-1252.
Osband et al., Problems in the investigational study and clinical use of cancer immunotherapy, Immunology Today, 1990, 11(6):193-195.
Rivoltini et al., Binding and Presentation of Peptides Derived from Melanoma Antigens MART-1 and Glycoprotein-100 by HLA-A2 Subtypes, Journal of Immunology, May 1996, pp. 3882-3891.
Marchand et al., Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3, Int. J. Cancer, 1995 63, 883-885, Wiley-Liss, Inc.
Rosenberg et al., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nature Medicine, Mar. 1998, vol. 4, No. 3, pp. 321-327.
Rosenberg, Cancer vaccines based on the identification of genes encoding cancer regression antigens, Immunology Today, vol. 18, No. 4, Apr. 1997, pp. 175-182.
Salgaller et al., Immunization against Epitopes in the Human Melanoma Antigen gp100 following Patient Immunization with Synthetic Peptides, Cancer Research, Oct. 1996, pp. 4749-4757, vol. 56.
Sinkovics et al., Vaccination against human cancers (review), International Journal of Cancer, 2000, pp. 81-96, vol. 16.
Slingluff et al., Melanomas with concordant loss of multiple differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens, Cancer Immunology & Immunotherapy, 2000, pp. 661-672, vol. 48, No. 12.
Slingluff et al., Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes Is Mediated by at Least Six Shared Peptide Epitopes, The Journal of Immunology, Apr. 1, 1993, pp. 2955-2963, vol. 150, No. 7, The American Association of Immunologists, USA.
Splitler, Le, Cancer vaccines: the interferon analogy, Cancer Biotherapy, 1995, pp. 1-3, vol. 10, No. 1.
Tao et al., Studies of Aglycosylated Chimeric Mouse-Human IgG, J. Immunol, 1989, vol. 143, No. 8, pp. 2595-2601.
Timmerman et al., Dendritic cell vaccines for cancer immunotherapy, Annual Review of Medicine, 1999, pp. 507-529, vol. 50.
Vogel et al., Human 95kD melanocyte-specific secreted glycoprotein mRNA, 3′ end EMBL Database, Accession No. M32295, Nov. 26, 1990.
Yamshchikov et al., Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations, Clinical Cancer Research, pp. 909s-916s, vol. 7, No. 3 supplement, 2001.
Zaks et al., Immunization with a peptide epitope (p. 369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors, Cancer Research, pp. 4902-4908, vol. 58, 1998.
Bocchia Ia et al., Abstract, Specific binding of leukemia oncogene fusion protein peptides to H class I molecules, Blood, May 15, 1995, pp. 2680-2684, vol. 85, No. 10.
Bristow et al., Abstract, Solid-phase antigen binding by purified immunoproteins from antigen-specific monoclonal T cell hybridomas, Mol. Immunol. Jul. 1989, pp. 611-624, vol. 26, No. 7.
Gether et al., Abstract, Stable expression of high affinity NK1 (substance P) and NK2 (neurokinin A) receptors but low affinity NK3 (neurokinin B) receptors in transfected CHO cells, FEBS Letters, Jan. 27, 1992, pp. 241-44, vol. 296, No. 3.
Hartwell et al., Integrating Genetic Approaches into the Discovery of Anticancer Drugs, Science, Nov. 7, 1997, pp. 1064-1068, vol. 278.
Lilly et al., Abstract, Effects of chronic airway inflammation on the activity and enzyme inactivation of neuropeptides in guinea pig lungs, J. Clin. Invest, Jun. 1994, pp. 2667-2674, vol. 93, No. 6.
Phan et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, PNAS, Jul. 8, 2003, pp. 8372-8377, vol. 100, No. 14.
Rosenberg et al., Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine, 1999, The Journal of Immunology, pp. 1690-1695.
Rosenberg, Steven A., Progress in human tumour immunology and immunotherapy, Nature, May 17, 2001, pp. 380-384, vol. 411.
Adema et al., Melanocyte Lineage-Specific Antigens Recognized by Monoclonal Antibodies NKI-beteb, HMB-50, and HMB-45 are Encoded by a Single cDNA, American Journal of Pathology, Dec. 1993, pp. 1579-1585, vol. 143, No. 6.
Adema et al., T Cell Stimulatory Tumor Antigens, Keystone Symposium; 1993, J. Cell Biochem, supplement 17, part D, p. 107.
Shilyansky et al., T-cell receptor usage bymelanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines, Proc. Natl. Acad. Sci., Mar. 1994, pp. 2829-2833, vol. 91.
Storkus et al., Identification of Human Melanoma Peptides Recognized by Class I Restricted Tumor Infiltrating T Lymphocytes, The Journal of Immunology, Oct. 1, 1993, pp. 3719-3727, vol. 151, No. 7, USA.
O'Neil et al., Detection of Shared MHC-Restricted Human Melanoma Antigens after Vaccinia Virus-Mediated Transduction of Genes Coding for HLA, Aug. 1, 1993, pp. 1410-1418, vol. 151, USA.
Kawakami et al., T-Cell Recognition of Human Melanoma Antigens, Journal of Immunotherapy, 1993, pp. 88-93, vol. 14, Raven Press, Ltd., New York.
Miles et al., HiTech . . . Multiple Peptide Synthesis (Pepscan Method) for the Systematic Analysis of B- and T-cell Epitopes: Application to Parasite Proteins, Parasitology Today, 1989, vol. 5, No. 12.
Arnholdt et al., Analysis and Partial Epitope Mapping of Human T Cell Responses to Trypanosoma cruzi Cysteinyl Proteinase, The Journal of Immunology, Sep. 15, 1993, pp. 3171-3179, vol. 151, No. 6, USA.
Reynolds et al., T and B Cell Epitope Mapping of SM23, an Integral Membrane Protein of Schistosoma mansoni, The Journal of Immunology, Dec. 15, 1992, pp. 3995-4001, vol. 149, No. 12, USA.
Kawakami et al., Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection, Proc. Natl. Acad. Sci. Jul. 1994, pp. 6458-6462, vol. 91, USA.
Bakker et al., Melanocyte Lineage-specific Antigen gp100 Is Recognized by Melanoma-derived Tumor-infiltrating Lymphocytes, The Journal of Experimental Medicine, Mar. 1994, pp. 1005-1009, vol. 179.
NCBI. Gen Bank. Accession No. M77348., Jan. 8, 1995.
Hunt et al., Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry, Science, pp. 1261-1263, vol. 255, 1992.
Adema et al., Molecular Characterization of the Melanocyte Lineage-specific Antigen gp100, Aug. 5, 1994, pp. 20126-20133, vol. 269, No. 31, USA.
Kawakami et al., Immunobiology of Human Melanoma Antigens MART-1 and gp100 and their Use of Immuno-Gene Therapy, Intern. Rev. Immunol, pp. 173-192, vol. 14, Overseas Publishers Association, Amsterdam, The Netherlands, Feb. 1997.
Kawakami et al., Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression, The Journal of Immunology, 1995, pp. 3961-3968, vol. 154.
Traversari, C., et al., “A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed against Tumor Antigen MZ2-E”, J. Exp. Med., vol. 176, 1453-1457 (Nov. 1992).
Notice of Opposition to European Patent No. EP0668350; Date of mention of the grant in the European Patent Bulletin Jul. 28, 2004, publicly available through EPO Register Plus website
MPSRCH Search Report Seq ID No. 22, p. 1-3 (2001).
MPSRCH Search Report, for Seq ID No. 21, p. 1-2 (2001).
Altschul, S.F. et al. (1990) J. Mol. Biol. 215, pp. 403-410.
Anderson et al. (2000) Tissue Antigens 55(6), pp. 519-531.
Anichini, A., et al., (1993), J. Exp. Med. 177, pp. 989-998.
Baker, S.J. et al. (1990), Science 249, pp. 912-915.
Bean, M.A. et al. (1975) Cancer Res. 35, pp. 2902-2907.
Bowie et al., (1990), Science, 257, pp. 1306-1310.
Brichard et al. (1993) J. Exp. Med. 178, pp. 489-495.
Chirgwin, J.M. et al. (1979) Biochemistry 18, pp. 5294-5299.
Cleveland, D.W. et al. (1977) J. Biol. Chem. 253, pp. 1102-1106.
Cox, A.L. et al. (1994) Science 264, pp. 716.
Dadaglio, G. et al. (1991) J. Immunol. 147, pp. 2302.
Devereux, J. et al. (1984) Nucleic Acids Res. 12, pp. 387.
Eisinger, M. et al. (1982) Proc. Nat'l. Acad. Sci. USA 79, pp. 2018-2022.
Espevik and Nissen-Meyer (1986) J. Immunol. Meth. 95, pp. 99.
Esclamado, R.M. et al. (1986) Am. J. Surg. 152, pp. 376-385.
Falk, K. et al. (1991) Nature 351, pp. 290.
Felgner, P.L. et al. (1987) Proc. Nat'l. Acad. Sci. USA 84, pp. 7413-7417.
Feltkamp et al. (1994) Mol. Immunol. 31(18), pp. 1391-1401.
Fisher, B. et al. (1989), J. Clin. Oncol. 7, pp. 250-261.
Gotch, F. et al. (1987) Nature 326, pp. 881.
Graham, F.L. et al. (1973), Virology 52, pp. 456.
Green, M.R. (1991) Ann. Rev. Cell Biol. 7, pp. 559-599.
Guichard et al. (2000) J. Med Chem. 43, pp. 3803-3808.
Haisma, H.J. et al. (1986) J. Nucl. Med. 27, pp. 1890.
Hall, R. et al. (1984) Nature 311, pp. 379-387.
Hnatowich, D.J. et al. (1983) J. Immunol. Meth. 65, pp. 147-157.
Holmes (2001) Expert Opinion on Investigational Drugs, pp. 511-519.
Jones, P.T. et al. (1986) Nature 321, pp. 522-525.
Katano, M. et al. (1984) J. Cancer Res. Clin. Oncol. 108, pp. 197.
Kim, R.Y. et al. (1992) Exp. Eye Res. 55, pp. 657-662.
Kohler, G. et al. (1975) Nature 256; pp. 495-497.
Knuth, A. et al. (1992) Cancer Surveys pp. 39-52.
Kozak, M. (1987) Nucleic Acids Res. 15, pp. 8125-8148.
Ksander, B.R. et al. (1991) Investigative Ophtamology & Visual Science, 32, pp. 3198-3208.
Kwon, B.S. et al. (1987) Mol. Biol. Med. 4, pp. 339-355.
Kyte, J. et al. (1982) J. Mol. Biol. 157, pp. 105-132.
Lenstra, J.A. et al. (1990), Arch. Virol. 110, pp. 1-24.
Loenen, W.A.M. et al. (1991) Eur. J. Immunol. 22, pp. 447.
McCoullough et al., (2005) Ilar J., 46(3) pp. 230-240.
Mochii, M. et al. (1991) Pigment Cell Res. 4, pp. 41-47.
Old, L., Cancer Res (1981) 41, pp. 361-375.
Nijman et al. (1993), Eur. J. Immunol. 23, pp. 1215.
Padgett, R.A. et al. (1986) Ann. Rev. Biochem. 55, pp. 119-1150.
Pearson, W.R. et al. (1988) Proc. Nat'l. Acad. Sci. USA 85, pp. 2444-2448.
Proudfoot, N.J. et al. (1976) Nature 263, pp. 211-214.
Rosenberg, S.A. et al. (1986), Science 223, pp. 1318-1321.
Ruppert, J. et al. (1993) Cell 74, pp. 929.
Ruskin, B. et al. (1984) Cell 38, pp. 317-331.
Sanger, F. et al. (1977) Proc. Nat'l. Acad. Sci. USA 74, pp. 5463-5467.
Schirle et al., (2001) J. Immunol. Methods 257, pp. 1-16.
Schwartz, R.H. (1992) Cell 71, pp. 1065-1068.
Seed, B. et al. (1987) Proc. Nat'l. Acad. Sci. USA 84, pp. 3365.
Smit, N. et al. (1993) Arch. Dermatol. Res. 285, pp. 356-365.
Topalian, S.L. et al. (1987), J. Immunol. Meth. 102, pp. 127-141.
Townsend, A.R.M. et al. (1989), Ann. Rev. Immunol. 7, pp. 601-624.
Tsomides, T.J. et al. (1991) Proc. Nat'l Acad. Sci. USA 88, pp. 11276.
van Der Burg et al., (1996) J. immunol. 156(9), pp. 3308-3314.
van Muijen, G.N.P. et al. (1991) Clin. Expl. Metast. 9, pp. 259-272.
Vennegoor, C. et al. (1988) Am. J. Pathol. 130, pp. 179-192.
Vogel, A.M. et al. (1988) Cancer Res. 48, pp. 1286-1294.
von Heijne, G. (1986) Nucleic Acids Res. 14, pp. 4683-4690.
Adema, G.J. et al. (1991) Biochem. Biophys. Res. Comm. 178, pp. 985-992.

Referenced By

The current document is not referenced by other documents.

Patent Family

The current document is not in a family.